Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease
暂无分享,去创建一个
A. d’Arminio Monforte | G. Marchetti | M. Cozzolino | A. Barassi | P. Ciceri | A. Galassi | L. Magagnoli | M. Sala | V. Bono
[1] T. Benfield,et al. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3 , 2022, Journal of Innate Immunity.
[2] A. Larsson,et al. Soluble TNF receptors predict acute kidney injury and mortality in critically ill COVID-19 patients: A prospective observational study , 2021, Cytokine.
[3] J. Berzofsky,et al. IL-7 in SARS-CoV-2 Infection and as a Potential Vaccine Adjuvant , 2021, Frontiers in immunology.
[4] Lanjuan Li,et al. Cytokine Signature Associated With Disease Severity in COVID-19 , 2021, Frontiers in Immunology.
[5] C. Ronco,et al. Classification of Uremic Toxins and Their Role in Kidney Failure. , 2021, Clinical journal of the American Society of Nephrology : CJASN.
[6] A. Cossarizza,et al. Cell Death in Coronavirus Infections: Uncovering Its Role during COVID-19 , 2021, Cells.
[7] A. Mantovani,et al. PTX3 Regulation of Inflammation, Hemostatic Response, Tissue Repair, and Resolution of Fibrosis Favors a Role in Limiting Idiopathic Pulmonary Fibrosis , 2021, Frontiers in Immunology.
[8] M. Cozzolino,et al. Expanded Haemodialysis as a Current Strategy to Remove Uremic Toxins , 2021, Toxins.
[9] T. van der Poll,et al. Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients , 2021, Frontiers in Immunology.
[10] J. Danesh,et al. Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19 , 2021, medRxiv.
[11] L. Rénia,et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients , 2021, Open forum infectious diseases.
[12] B. Ma,et al. Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19 , 2021, bioRxiv.
[13] A. Avery,et al. Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 may be predictive of death in Severe Coronavirus Disease 2019 (COVID-19) , 2020, The Journal of infectious diseases.
[14] R. Webby,et al. Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes , 2020, Cell.
[15] R. Vasan,et al. Association of Multiple Plasma Biomarker Concentrations with Progression of Prevalent Diabetic Kidney Disease: Findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. , 2020, Journal of the American Society of Nephrology : JASN.
[16] L. Sağlam,et al. Evaluation of alpha defensin, IL‐1 receptor antagonist, and IL‐18 levels in COVID‐19 patients with macrophage activation syndrome and acute respiratory distress syndrome , 2020, Journal of medical virology.
[17] M. Ardalan,et al. Covid‐19 and kidney injury: Pathophysiology and molecular mechanisms , 2020, Reviews in medical virology.
[18] G. Erbaş,et al. Prognostic value of interleukin-18 and its association with other inflammatory markers and disease severity in COVID-19 , 2020, Cytokine.
[19] Kenneth G. C. Smith,et al. Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection , 2020, Journal of proteome research.
[20] R. Hotchkiss,et al. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts Among Patients With Severe Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.
[21] C. Peano,et al. Macropahge expression and prognostic significance of the long pentraxin PTX3 in COVID-19 , 2020, medRxiv.
[22] B. Zhu,et al. Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China , 2020, The Journal of infectious diseases.
[23] S. Metcalfe. COVID-19 lockdown: de-risking exit by protecting the lung with leukaemia inhibitory factor (LIF) , 2020, Medicine in Drug Discovery.
[24] E. Coomes,et al. Interleukin‐6 in Covid‐19: A systematic review and meta‐analysis , 2020, medRxiv.
[25] L. G. Vu,et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.
[26] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[27] R. Zemans,et al. Transitional human alveolar type II epithelial cells suppress extracellular matrix and growth factor gene expression in lung fibroblasts. , 2019, American journal of physiology. Lung cellular and molecular physiology.
[28] J. Barata,et al. Flip the coin: IL-7 and IL-7R in health and disease , 2019, Nature Immunology.
[29] M. Malaise,et al. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature , 2019, Rheumatology.
[30] Cheng-Hsien Lu,et al. α-1-Acid Glycoprotein Concentration as an Outcome Predictor in Adult Patients with Sepsis , 2019, BioMed research international.
[31] F. Rieux-Laucat,et al. FAS and RAS related Apoptosis defects: From autoimmunity to leukemia , 2018, Immunological reviews.
[32] Ling Wang,et al. Effects of interleukin‐7/interleukin‐7 receptor on RANKL‐mediated osteoclast differentiation and ovariectomy‐induced bone loss by regulating c‐Fos/c‐Jun pathway , 2018, Journal of cellular physiology.
[33] G. Kaplanski. Interleukin‐18: Biological properties and role in disease pathogenesis , 2017, Immunological reviews.
[34] G. Hejblum,et al. Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.
[35] R. Gress,et al. An overview of IL-7 biology and its use in immunotherapy , 2010, Journal of immunotoxicology.
[36] A. El-Agroudy,et al. Soluble Fas: a useful marker of inflammation and cardiovascular diseases in uremic patients , 2010, Clinical and Experimental Nephrology.
[37] Lorien S. Dalrymple,et al. Epidemiology of acute infections among patients with chronic kidney disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[38] Toshio Tanaka,et al. T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production , 2007, Proceedings of the National Academy of Sciences.
[39] J. Scheller,et al. Interleukin-6 and its receptor: from bench to bedside , 2006, Medical Microbiology and Immunology.
[40] J. Clark,et al. What does tumour necrosis factor excess do to the immune system long term? , 2005, Annals of the rheumatic diseases.
[41] T. Saruta,et al. Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. , 2003, Journal of the American Society of Nephrology : JASN.
[42] M. Weiser,et al. α1-Acid glycoprotein reduces local and remote injuries after intestinal ischemia in the rat. , 1997, American journal of physiology. Gastrointestinal and liver physiology.
[43] P. Marik,et al. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-α as predictive factors for ARF in patients with septic shock , 2003 .